Jiedu Xiaozheng Yin, a Chinese herbal formula, inhibits tumor angiogenesis via downregulation of VEGF-A and VEGFR-2 expression in vivo and in vitro

Cao,Zhiyun; Lin,Wei; Huang,Zhengrong; Chen,Xuzheng; Zhao,Jinyan; Zheng,Liangpu; Ye,Hongzhi; Liu,Zhizhen; Liao,Lianming; Du,Jian

doi:10.3892/or.2012.2202

Jiedu Xiaozheng Yin, a Chinese herbal formula, inhibits tumor angiogenesis via downregulation of VEGF-A and VEGFR-2 expression in vivo and in vitro

Authors:
- Zhiyun Cao
- Wei Lin
- Zhengrong Huang
- Xuzheng Chen
- Jinyan Zhao
- Liangpu Zheng
- Hongzhi Ye
- Zhizhen Liu
- Lianming Liao
- Jian Du
View Affiliations

Affiliations: Fujian Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350108, P.R. China, Integrated Chinese and Western Medicine Department, Fujian Provincial Cancer Hospital, Minhou Shangjie, Fuzhou, Fujian 350108, P.R. China
Published online on: December 19, 2012 https://doi.org/10.3892/or.2012.2202
Pages: 1080-1086

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Angiogenesis is crucial for cancer growth and metastasis and inhibition of angiogenesis has been recognized to be a promising strategy for the treatment of cancer. Traditional Chinese medicine (TCM) has been used for thousands of years to treat cancer. Jiedu Xiaozheng Yin (JXY), a polyherbal formula of TCM, has been used to treat various tumors in China. However, the mechanism of its anticancer activity has yet to be fully elucidated. Using human umbilical vein endothelial cells (HUVECs), chick chorioallantoic membrane (CAM) and a hepatoma mouse xenograft model, we investigated the underlying molecular mechanisms of ethanol extract of Jiedu Xiaozheng Yin (EE-JXY). EE-JXY treatment significantly inhibited tumor cell growth both in vitro and in the mouse xenograft model (P<0.05). Moreover, EE-JXY reduced tube formation of HUVECs and angiogenesis in the CAM (P<0.01) and microvessel density (MVD) of tumor in vivo (P<0.05). Further studies showed that EE-JXY was able to suppress the expression of vascular endothelial growth factor A (VEGF-A) and vascular endothelial growth factor receptor 2 (VEGFR-2) in both HepG2 cells and HUVECs (P<0.01) and in tumor (P<0.01). Thus, JXY suppressed tumor growth at least by inhibiting angiogenesis.

View Figures

View References

1	Zhao J, Jiang P and Zhang WD: Molecular networks for the study of TCM Pharmacology. Brief Bioinform. 11:417–430. 2010. View Article : Google Scholar : PubMed/NCBI
2	Ji HF, Li XJ and Zhang HY: Natural products and drug discovery. Can thousands of years of ancient medical knowledge lead us to new and powerful drug combinations in the fight against cancer and dementia? EMBO Rep. 10:194–200. 2009.PubMed/NCBI
3	Longley DB, Allen WL and Johnston PG: Drug resistance, predictive markers and pharmacogenomics in colorectal cancer. Biochim Biophys Acta. 1766:184–196. 2006.PubMed/NCBI
4	Yan Y, Cook J, McQuillan J, Zhang G, Hitzman CJ, Wang Y, Wiedmann TS and You M: Chemopreventive effect of aerosolized polyphenon E on lung tumorigenesis in A/J mice. Neoplasia. 9:401–405. 2007. View Article : Google Scholar : PubMed/NCBI
5	Fang Y, Zhang Y, Chen M, Zheng H and Zhang K: The active component of Hedyotis diffusa Willd. Chin Trad Plant Med. 26:577–579. 2004.
6	Wu YG and Song LR: Shanghai Science and Technology Press. Zhong Hua Ben Cao. 25:530–533. 1998.(In Chinese).
7	Lin J, Wei L, Xu W, Hong Z, Liu X and Peng J: Effect of Hedyotis Diffusa Willd extract on tumor angiogenesis. Mol Med Rep. 4:1283–1288. 2011.
8	Lin J, Chen Y, Wei L, Chen X, Xu W, Hong Z, Sferra TJ and Peng J: Hedyotis Diffusa Willd extract induces apoptosis via activation of the mitochondrion-dependent pathway in human colon carcinoma cells. Int J Oncol. 37:1331–1338. 2010.
9	Chen XZ, Cao ZY, Chen TS, Zhang YQ, Liu ZZ, Su YT, Liao LM and Du J: Water extract of Hedyotis Diffusa Willd suppresses proliferation of human HepG2 cells and potentiates the anticancer efficacy of low-dose 5-fluorouracil by inhibiting the CDK2-E2F1 pathway. Oncol Rep. 28:742–748. 2012.
10	Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
11	Folkman J: Angiogenesis. Annu Rev Med. 57:1–18. 2006. View Article : Google Scholar
12	Fava RA, Olsen NJ, Spencer-Green G, Yeo TK, Yeo KT, Berse B, Jackman RW, Senger DR, Dvorak HF and Brown JF: Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med. 180:341–346. 1994. View Article : Google Scholar : PubMed/NCBI
13	McLaren J, Prentice A, Charmock-Jones DS, Millican SA, Muller KH, Sharkey AM and Smith SK: Vascular endothelial growth factor is produced by peritoneal fluid macrophages in endometriosis and is regulated by ovarian steroids. J Clin Invest. 98:482–489. 1996. View Article : Google Scholar : PubMed/NCBI
14	Shweiki D, Itin A, Soffer D and Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 359:843–845. 1992. View Article : Google Scholar : PubMed/NCBI
15	Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Britman ML and Schuh AC: Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature. 376:62–66. 1995. View Article : Google Scholar : PubMed/NCBI
16	Kim KF, Li B, Winer J, Armanin M, Gillet N, Philips HS and Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 36:841–844. 1993. View Article : Google Scholar : PubMed/NCBI
17	Yano S, Shinohara H, Herbst RS, Kuniyasu H, Bucana CD, Ellis LM, Davis DW, McConkey DJ and Fidler IJ: Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis. Cancer Res. 60:4959–4967. 2000.PubMed/NCBI
18	Li P, Zhang M, Ma WJ, Sun X and Jin FP: Effects of brucine on vascular endothelial growth factor expression and microvessel density in a nude mouse model of bone metastasis due to breast cancer. Chin J Integr Med. 18:605–609. 2012. View Article : Google Scholar : PubMed/NCBI
19	Shen AL, Hong F, Liu LY, Lin JM, Zhuang QC, Hong ZF and Peng J: Effects of Pien Tze Huang (PTH) on angiogenesis in vivo and in vitro. Chin J Integr Med. 18:431–436. 2012. View Article : Google Scholar : PubMed/NCBI
20	Chen LW, Lin J, Chen W and Zhang WP: Effect of Chinese herbal medicine on patients with primary hepatic carcinoma in III stage during perioperational period: a report of 42 cases. Zhongguo Zhong Xi Yi Jie He Za Zhi. 25:832–834. 2005.(In Chinese).
21	Ellis LM and Hicklin DJ: VEGF-targeted therapy: mechanisms of antitumour activity. Nat Rev Cancer. 8:579–591. 2008. View Article : Google Scholar : PubMed/NCBI
22	Kerbel RS, Yu J, Tran J, Man S, Viloria-Petit A, Klement G, Coomber BL and Rak J: Possible mechanisms of acquired resistance to antiangiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev. 20:79–86. 2001. View Article : Google Scholar : PubMed/NCBI
23	Miller KD, Sweeney CJ and Sledge GW: Can tumor angiogenesis be inhibited without resistance? EXS. 95–112. 2005.PubMed/NCBI
24	Carmeliet P: VEGF as a key mediator of angiogenesis in cancer. Oncology. 69:4–10. 2005. View Article : Google Scholar : PubMed/NCBI
25	Lee S, Chen TT, Barber CL, Jordan MC, Murdock J, Desai S, Ferrara N, Nagy A, Roos KP and Iruela-Arispe ML: Autocrine VEGF signaling is required for vascular homeostasis. Cell. 130:691–703. 2007. View Article : Google Scholar : PubMed/NCBI
26	Kerbel RS: Tumor angiogenesis. N Engl J Med. 358:2039–2049. 2008. View Article : Google Scholar : PubMed/NCBI
27	Hisa T, Kimura Y, Takada K, Suzuki F and Takigawa M: Shikonin: an ingredient of Lithospermum erythrorhizon, inhibits angiogenesis in vivo and in vitro. Anticancer Res. 18:783–790. 1998.
28	Yoon TJ, Yoo YC, Choi OB, Do MS, Kang TB, Lee SW, Azuma I and Kim JB: Inhibitory effect of Korean mistletoe (Viscum album coloratum) extract on tumour angiogenesis and metastasis of haematogenous and non-haematogenous tumour cells in mice. Cancer Lett. 97:83–91. 1995.
29	Alves De Paulo S, Teruszkin Balassiano I, Henriques Silva N, Oliveira Castilho R, Coelho Kaplan MA, Currie Cabral M and da Costa Carvalho MG: Chrysobalanus icaco L. extract for antiangiogenic potential observation. Int J Mol Med. 5:667–669. 2000.
30	Kim MS, Lee YM, Moon EJ, Kim SE, Lee JJ and Kim KW: Anti-angiogenic activity of torilin, a sesquiterpene compound isolated from Torilis japonica. Inl J Cancer. 87:269–275. 2000. View Article : Google Scholar : PubMed/NCBI
31	Kimura Y, Baba K and Okuda H: Inhibitory effects of active substances isolated from Cassia garrettiana heartwood on tumor growth and lung metastasis in Lewis lung carcinoma-bearing mice (part 1). Anticancer Res. 20:2899–2906. 2000.PubMed/NCBI
32	Takaku T, Kimura Y and Okuda H: Isolation of an antitumor compound from Agaricus blazei Murill and its mechanism of action. J Nutr. 131:1409–1413. 2001.PubMed/NCBI
33	Casaletto JB and McClatchey AI: Spatial regulation of receptor tyrosine kinases in development and cancer. Nat Rev Cancer. 12:387–400. 2012. View Article : Google Scholar : PubMed/NCBI
34	Sastry SK and Elferink LA: Checks and balances: interplay of RTKs and PTPs in cancer progression. Biochem Pharmacol. 82:435–440. 2011. View Article : Google Scholar : PubMed/NCBI
35	Casanovas O, Hicklin DJ, Bergers G and Hanahan D: Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell. 8:299–309. 2005. View Article : Google Scholar : PubMed/NCBI
36	Faivre S, Ronot M, Dreyer C, Serrate C, Hentic O, Bouattour M, Bruno O, Couvelard A, Vilgrain V and Raymond E: Imaging response in neuroendocrine tumors treated with targeted therapies: the experience of sunitinib. Target Oncol. 7:127–133. 2012. View Article : Google Scholar : PubMed/NCBI
37	Escudier B, Szczylik C, Porta C and Gore M: Treatment selection in metastatic renal cell carcinoma: expert consensus. Nat Rev Clin Oncol. 9:327–337. 2012. View Article : Google Scholar : PubMed/NCBI
38	Zheng LP, Hu HX, Lin W, Huang YM, Zhao JY and Chen WL: The effect of serum of Jiedu Xiaozheng Yin on proliferation of gastric carcinoma cell line. Pharmacology and Clinics of Chinese Materia Medica. 25:91–93. 2009.(In Chinese).
39	Chen XZ and Du J: The effect of Jiedu Xiaozheng drink on HepG2 cells mitochondrial membrane potential. Journal of Fujian University of TCM. 19:22–23. 2009.(In Chinese).
40	Chen L, Zheng C and Du J: Study on antitumor mechanism of Qingre Xiaozheng drink by molecular docking method. Clin Pharmacol Ther. 12:324–328. 2007.